Chapter 4. European guidelines for the management of chronic nonspecific low back pain.
Olavi Airaksinen,J. I. Brox,Christine Cedraschi,J. Hildebrandt,J. Klaber-Moffett,Francisco M. Kovacs,Anne F. Mannion,Shmuel Reis,J. B. Staal,Holger Ursin,Gustavo Zanoli +10 more
About:
This article is published in European Spine Journal.The article was published on 2006-03-01 and is currently open access. It has received 2219 citations till now. The article focuses on the topics: Back pain & Low back pain.read more
Citations
More filters
Journal ArticleDOI
Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society
TL;DR: This guideline is to present the available evidence for evaluation and management of acute and chronic low back pain in primary care settings and grades its recommendations by using the ACP's clinical practice guidelines grading system.
Journal ArticleDOI
painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain
TL;DR: Simple, patient-based, easy-to-use screening questionnaires can determine the prevalence of neuropathic pain components both in individual LBP patients and in heterogeneous cohorts of such patients.
Journal ArticleDOI
Non-specific low back pain
TL;DR: Two treatment strategies are currently used, a stepped approach beginning with more simple care that is progressed if the patient does not respond, and the use of simple risk prediction methods to individualise the amount and type of care provided.
Journal ArticleDOI
2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group
TL;DR: Instead of recommending Levels of Evidence, this update adopts the GRADE approach to determine the overall quality of the evidence for important patient-centered outcomes across studies and includes a new section on updating reviews.
Journal ArticleDOI
Non-specific low back pain
TL;DR: The lifetime prevalence of low back pain is reported to be as high as 84%, and the prevalence of chronic low back disease is about 23%, with 11-12% of the population being disabled by low back problems as mentioned in this paper.
References
More filters
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art
TL;DR: In this article, the authors reviewed the existing evidence for the mediating role of pain-related fear, and its immediate and long-term consequences in the initiation and maintenance of chronic pain disability.
Journal Article
Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art.
TL;DR: A review of the existing evidence for the mediating role of pain‐related fear, and its immediate and long‐term consequences in the initiation and maintenance of chronic pain disability, and the implications of the recent findings for the prevention and treatment of chronic musculoskeletal pain.
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.